Litifilimab
Monoclonal antibody
Evidence outlook · registrational
Systemic Lupus Erythematosus: registrational readout pending
Entered Phase 3 on reliable signal mid-stage evidence. The registry's posted readout date (2026-09-30) has passed without a status update. Check News for topline announcements.
LILAC (NCT02847598): This was a randomized, double-blind (participant and investigator), placebo-controlled trial with 264 enrolled participants and hard clinical primary endpoints (28-joint active joint count and CLASI-A skin activity score). The primary comparisons reached statistical significance in the favorable direction: Part A 450 mg vs placebo active-joint LS mean difference -3.4 (95% CI -6.7 to -0.2, p=0.037), and Part B CLASI-A LS mean differences -24.29 to -33.42 (p=0.015 to <0.001 across doses).
Company guidance: data expected first half of 2027 (NCT05531565; Biogen, 2 Oct 2026). “Results from the Phase 3 part of AMETHYST are expected in the first half of 2027; in January 2026 the FDA granted Breakthrough Therapy Designation to litifilimab in CLE” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
LILAC NCT02847598 · Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus This was a randomized, double-blind (participant and investigator), placebo-controlled trial with 264 enrolled participants and hard clinical primary endpoints (28-joint active joint count and CLASI-A skin activity score). The primary comparisons reached statistical significance in the favorable direction: Part A 450 mg vs placebo active-joint LS mean difference -3.4 (95% CI -6.7 to -0.2, p=0.037), and Part B CLASI-A LS mean differences -24.29 to -33.42 (p=0.015 to <0.001 across doses). Registry: NCT02847598 | 2 | Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24); Part B: Percent Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score to Week 16 (Baseline to Week 16) 2019-08-28 | Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24): Part A: BIIB059 50 mg -9 joints (Standard Deviation 5.7) | Part A: BIIB059 150 mg -13 joints | Part A: BIIB059 450 mg -14.5 joints (Standard Deviation 8.7) vs Part A: Placebo -12.7 joints (Standard Deviation 10.3) | Reliable signal | link ↗ |
View 3 more trials
TOPAZ-1 NCT04895241 · Lupus Erythematosus, Systemic Registry: NCT04895241 | 3 | Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52 2026-09-30 | Results not posted; external-source review pending | not yet graded | link ↗ |
TOPAZ-2 NCT04961567 · Lupus Erythematosus, Systemic Registry: NCT04961567 | 3 | Percentage of Participants Who Achieved a Systemic Lupus Erythematosus Responder Index of 4 (SRI-4) Response at Week 52 2026-09-27 | Results not posted; external-source review pending | not yet graded | link ↗ |
NCT02106897 NCT02106897 · Systemic Lupus Erythematosus, Healthy Volunteers This early-phase study randomly assigned healthy volunteers and people with systemic lupus erythematosus to litifilimab or matching placebo under quadruple-blind conditions across a series of dose cohorts, tracking adverse events as the primary outcome rather than a disease-activity endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants that Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT02106897 | 1 | Number of Participants that Experience Adverse Events (AEs) and Serious Adverse Events (SAEs) (Up to Week 32) 2016-05-24 | Maximum observed concentration and area under the concentration-time curve increased with dose following single intravenous administration (0.05 mg/kg to 20 mg/kg), with target-mediated clearance observed at lower doses (below 1 mg/kg) and saturated at doses >=1 mg/kg. In people with SLE the therapy safely reduced type I interferon levels, inflammation and skin lesions. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other BDCA2 (CLEC4C) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Systemic Lupus Erythematosus: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Litifilimab: this drug | Phase 3 | Monoclonal antibody | BDCA2 / CD303 (blood dendritic cell antigen 2), BDCA2 (CLEC4C) | Reliable signal | NCT02847598: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24): Part A: BIIB059 50 mg -9 joints (Standard Deviation 5.7) | Part A: BIIB059 150 mg -13 joints | Part A: BIIB059 450 mg -14.5 joints (Standard Deviation 8.7) vs Part A: Placebo -12.7 joints (Standard Deviation 10.3) | |
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor subunit 1 (IFNAR1) | Partial signal | NCT04931563: Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo (Week 52): Anifrolumab 300mg 84/138 vs Placebo 46/138 NCT02446899: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 (Baseline; Week 52): Anifrolumab 300 mg 86/180 (47.8%) vs Placebo 57/182 (31.3%) | |
| Belimumab (GSK1550188) (Benlysta) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | Weak signal | NCT00410384: SRI response at Week 52: 43.2% with belimumab 10 mg/kg vs 33.5% with placebo (p=0.0167); 40.6% with belimumab 1 mg/kg vs 33.5% with placebo (p=0.0889). | |
| Hydroxychloroquine | Approved | Small molecule | Autophagy/lysosomal acidification | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Obinutuzumab Beta (Bejescin) | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Voclosporin (Lupkynis) | Phase 3 | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | Reliable signal | No reviewed efficacy summary in this indication | |
| Afimetoran | Phase 2 | Small molecule | TLR7/8 | not yet graded | No reviewed efficacy summary in this indication | |
| BI 3000202 | Phase 2 | Small molecule | cGAS (cyclic GMP-AMP synthase) | not yet graded | No reviewed efficacy summary in this indication | |
| Blinatumomab | Phase 2 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Envudeucitinib | Phase 2 | Small molecule | TYK2 | Partial signal | NCT05966480: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). missed | |
| Frexalimab | Phase 2 | Monoclonal antibody | CD40 ligand (CD40L / CD154) | not yet graded | No reviewed efficacy summary in this indication | |
| FT819 | Phase 2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ICG318 | Phase 2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Phase 2 | Monoclonal antibody | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Nomelcitinib (D-2570) | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Obexelimab | Phase 2 | Monoclonal antibody | CD19 / FcγRIIb | Partial signal | NCT02725515: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225 (Day 225): XmAb5871 21/50 vs Placebo 12/42 missed | |
| Sanritatug | Phase 2 | Monoclonal antibody | CD38 | Weak signal | No reviewed efficacy summary in this indication | |
| TQH3906 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| VENT-03 | Phase 2 | Small molecule | cGAS (cyclic GMP-AMP synthase) | not yet graded | No reviewed efficacy summary in this indication | |
| Zolacabtagene Autoleucel | Phase 2 | Cell therapy | — | not yet graded | No reviewed efficacy summary in this indication | |
| Aritinercept | Phase 1/2(overall) | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0120 | Phase 1/2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Beijing Biotech Anti-CD19 CAR-T | Phase 1/2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Budoprutug | Phase 1/2 | Monoclonal antibody | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| DS-7011a | Phase 1/2 | Monoclonal antibody | Toll-like receptor 7 (TLR7) (inhibitor) | Weak signal | NCT05638802: Treatment-emergent adverse events: 11/19 DS-7011a participants vs 4/6 placebo participants. | |
| Lisaftoclax | Phase 1/2 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 1/2 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1 | Antibody–drug conjugate | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-519 | Phase 1 | — | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ANX009 | Phase 1 | Antibody fragment | C1q | not yet graded | No reviewed efficacy summary in this indication | |
| AZD5492 | Phase 1 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| BCD-256 | Phase 1 | Monoclonal antibody | BDCA2 (CLEC4C) | not yet graded | No reviewed efficacy summary in this indication | |
| BCMA-CD19 Compound CAR (cCAR) T Cells | Phase 1 | Cell therapy | BCMA / CD19 | Weak signal | NCT05474885: All patients (12/13) who received an initial dose of 3x10^6 cCAR cells/kg were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR. Therapy was well tolerated with mild cytokine-release syndrome (no CRS above grade 1), and mean SLE Disease Activity Index 2000 (SLEDAI-2K) fell from 9.9 at baseline to 2.3 at 3 months. | |
| BZE2204 | Phase 1 | Cell therapy | CD19, CD22, and BCMA (tri-antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| Cevostamab | Phase 1 | Multispecific antibody | FcRH5 (FcRL5) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Cizutamig | Phase 1 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| CLN-978 | Phase 1 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 1 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| F01 | Phase 1 | Cell therapy | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4527363 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5926371 | Phase 1 | Biologic (subtype unspecified) | CD19 / CD20 (dual-antigen) with CD3 T-cell engagement | not yet graded | No reviewed efficacy summary in this indication | |
| HC022 | Phase 1 | — | — | Weak signal | No reviewed efficacy summary in this indication | |
| IC19 CAR-T | Phase 1 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| LBL-047 | Phase 1 | Protein / enzyme therapeutic | BDCA2 (CLEC4C) / TACI | not yet graded | No reviewed efficacy summary in this indication | |
| NIM-1324 | Phase 1(overall) | Small molecule | LANCL2 | not yet graded | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 1 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| PIT565 | Phase 1 | Multispecific antibody | CD19 x CD2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| SAR448501 | Phase 1 | Multispecific antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 1 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| UTAA09 | Phase 1 | Cell therapy | CD19 | Weak signal | No reviewed efficacy summary in this indication | |
| UTAA91 | Phase 1 | Cell therapy | CD19 (B cells) and PD-1+ pathogenic T cells | not yet graded | No reviewed efficacy summary in this indication | |
| Vonsetamig | Phase 1 | — | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| ZM001 | Phase 1 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| FT522 | —(overall) | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| GRI-0803 | —(overall) | Small molecule | Type 2 NKT cells (activator) | not yet graded | No reviewed efficacy summary in this indication | |
| AB-101 (AlloNK) | Discontinued | Cell therapy | Cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Cadefrecitinib | Discontinued | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| GLPG3970 | Discontinued | Small molecule | SIK2/3 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 61 furthest-along competitors are listed; 2 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Litifilimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.